Fontanet Bijou

1.6k total citations
46 papers, 467 citations indexed

About

Fontanet Bijou is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Fontanet Bijou has authored 46 papers receiving a total of 467 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pathology and Forensic Medicine, 21 papers in Genetics and 16 papers in Oncology. Recurrent topics in Fontanet Bijou's work include Lymphoma Diagnosis and Treatment (27 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Hematopoietic Stem Cell Transplantation (7 papers). Fontanet Bijou is often cited by papers focused on Lymphoma Diagnosis and Treatment (27 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Hematopoietic Stem Cell Transplantation (7 papers). Fontanet Bijou collaborates with scholars based in France, United States and Italy. Fontanet Bijou's co-authors include Steven Le Gouill, Guillaume Cartron, Jean‐Michel Boiron, Nöel Milpied, Emmanuel Gyan, Hervé Ghesquières, Bettina Fabiani, Christian Chabannon, Mohamad Mohty and Gilles Salles and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Fontanet Bijou

41 papers receiving 457 citations

Peers

Countries citing papers authored by Fontanet Bijou

Since Specialization

Citations

This map shows the geographic impact of Fontanet Bijou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fontanet Bijou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fontanet Bijou more than expected).

Fields of papers citing papers by Fontanet Bijou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fontanet Bijou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fontanet Bijou. The network helps show where Fontanet Bijou may publish in the future.

Co-authorship network of co-authors of Fontanet Bijou

This figure shows the co-authorship network connecting the top 25 collaborators of Fontanet Bijou. A scholar is included among the top collaborators of Fontanet Bijou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fontanet Bijou. Fontanet Bijou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma) 2025 ·JMIR Cancer ·Katell Le Dû, Adrien Chauchet, (unknown), Olivier Fitoussi, Fontanet Bijou, (unknown), (unknown), Cédric Rossi, Sylvain Carras, (unknown), (unknown), (unknown)	0
2	Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials 2025 ·Blood Cancer Journal ·(unknown), (unknown), Fanny Cherblanc, (unknown), (unknown), (unknown), Fontanet Bijou, Pierre Sesques, (unknown), Luc‐Matthieu Fornecker, (unknown), Sylvain Carras, Loïc Chartier, Aurélien Belot, Lucie Obéric, Fabrice Jardin, Benoît Tessoulin	0
3	Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma 2025 ·Journal of Clinical Oncology ·Nancy L. Bartlett, Uwe Hahn, Won Seog Kim, Isabelle Fleury, Kamel Laribi, Juan Bergua, Krimo Bouabdallah, (unknown), Fontanet Bijou, David MacDonald, Craig A. Portell, Hervé Ghesquières, Grzegorz S. Nowakowski, Christopher A. Yasenchak, (unknown), Linda Ho, (unknown), Michelle A. Fanale, Fei Jie, Jeong‐Ah Kim	7
4	Impact of socioeconomic individual and ecological factors on extreme diagnosis-to-treatment interval in diffuse large B-Cell lymphoma in the French real-world cohort REALYSA 2025 ·Cancer Epidemiology ·C. Cantrelle, Alexandre Bélot, (unknown), Fontanet Bijou, (unknown), (unknown), (unknown), (unknown), Hervé Ghesquières, Loïc Ysebaert, (unknown)	0
5	Are oldest old patients with diffuse large B-cell lymphoma different than their younger counterparts: Results from the REALYSA real-life cohort 2025 ·Cancer Epidemiology ·C. Cantrelle, Alexandre Bélot, (unknown), Fontanet Bijou, Cédric Rossi, (unknown), (unknown), Pierre Soubeyran, (unknown), Loïc Ysebaert, (unknown), (unknown)	1
6	Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study 2024 ·Blood ·Constantine S. Tam, Anna Maria Frustaci, Fontanet Bijou, (unknown), John F. Seymour, Masa Lasica, Herbert Eradat, (unknown), (unknown), Irina Mocanu, Xiangmei Chen, Kunthel By, (unknown), Daniel O. Persky, Amit Agarwal, Chan Y. Cheah	2
7	Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study. 2024 ·Journal of Clinical Oncology ·Jeong‐Ah Kim, Uwe Hahn, Won-Seog Kim, Isabelle Fleury, (unknown), (unknown), Krimo Bouabdallah, (unknown), Fontanet Bijou, David Macdonald, Craig A. Portell, Hervé Ghesquières, Grzegorz S. Nowakowski, Christopher A. Yasenchak, (unknown), Michelle A. Fanale, Fei Jie, Nancy L. Bartlett	3
8	Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients 2022 ·Cancers ·Elsa Maître, Cécile Tomowiak, (unknown), Fontanet Bijou, (unknown), (unknown), (unknown), Édouard Cornet, Pierre‐Julien Viailly, (unknown), Brigitte Sola, Fabrice Jardin, Xavier Troussard	10
9	Characteristics of cells with engraftment capacity within CD34+ cell population upon G-CSF and Plerixafor mobilization 2020 ·Leukemia ·(unknown), Laura Rodríguez, (unknown), Pascale Duchez, Marija Vlaski‐Lafarge, Christelle Debeissat, (unknown), Catherine M. Sawai, Jean‐Max Pasquet, Fontanet Bijou, (unknown), (unknown), Zoran Ivanović, Philippe Brunet de la Grange	6
10	Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma 2020 ·Blood ·Jean‐Marie Michot, Réda Bouabdallah, Jeanette K. Doorduijn, Carola Boccomini, Marie José Kersten, Annalisa Chiappella, Pier Luigi Zinzani, Gilles Salles, Fontanet Bijou, (unknown), (unknown), Patrick R. Hagner, Christian Klein, Michael Pourdehnad, Kristen Hege, (unknown), Zariana Nikolova, Vincent Ribrag	3
11	Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study 2019 ·The Lancet Haematology ·Franck Morschhauser, Steven Le Gouill, Pierre Feugier, Sarah Bailly, Emmanuelle Nicolas‐Virelizier, Fontanet Bijou, Gilles Salles, Hervé Tilly, Christophe Fruchart, Koen Van Eygen, Sylvia Snauwaert, Christophe Bonnet, Corinne Haïoun, Catherine Thiéblemont, Réda Bouabdallah, Ka Lung Wu, Danielle Canioni, Véronique Meignin, Guillaume Cartron, Roch Houot	61
12	Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia 2019 ·BMC Cancer ·(unknown), Françoise Durrieu, E. Martin, Michaël Pérès, François Vergez, Thomas Filleron, Lucie Obéric, Fontanet Bijou, Anne Quillet‐Mary, Loïc Ysebaert	14
13	Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors 2019 ·Cancer Medicine ·Gabriel Étienne, Stéphanie Dulucq, Françoise Huguet, Anna Schmitt, (unknown), Sandrine Hayette, (unknown), Pierre Sujobert, Fontanet Bijou, Stéphane Morisset, Suzanne Tavitian, Audrey Bidet, Béatrice Turcq, Fanny Robbesyn, Claudine Chollet, Françis Belloc, Françoise Durrieu, François‐Xavier Mahon, Franck E. Nicolini	15
14	Addition of plerixafor to G-CSF is useful to achieve efficient collection even in very poor mobilizers: hope for patients with diminished hematopoietic function 2017 ·Bone Marrow Transplantation ·Mohamad Mohty, (unknown), (unknown), Fontanet Bijou, Nöel Milpied, Christian Chabannon	4
15	The choice of in-hospital or home administration for plerixafor injection to poor mobilizers has no adverse consequence on subsequent hematopoietic stem cell harvest 2017 ·Bone Marrow Transplantation ·Christian Chabannon, Fontanet Bijou, (unknown), (unknown), Nöel Milpied, Mohamad Mohty	3
16	Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases 2016 ·Leukemia & lymphoma ·Anne‐Claire Gac, Nabih Azar, Étienne Daguindau, Guillaume Cartron, Luc Matthieu Fornecker, Emmanuel Gyan, Florence Broussais‐Guillaumot, Réda Garidi, Bachra Choufi, Sylvain Chantepie, Marie C. Béné, Romain Guièze, Fontanet Bijou, Rémy Gressin, Sandy Amorim, Gandhi Damaj	3
17	Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group 2016 ·Annals of Oncology ·Emmanuelle Tchernonog, (unknown), Paul Coppo, (unknown), (unknown), (unknown), (unknown), Jehan Dupuis, Fontanet Bijou, Charles Herbaux, Alain Delmer, Bettina Fabiani, Caroline Besson, Steven Le Gouill, Emmanuel Gyan, Camille Laurent, Hervé Ghesquières, Guillaume Cartron	78
18	Neonatal sex and weight influence CD34+ cell concentration in umbilical cord blood but not stromal cell–derived factor 1-3′A polymorphism 2014 ·Cytotherapy ·Fontanet Bijou, Zoran Ivanović, (unknown), Bernard Dazey, Jean‐Michel Boiron, Xavier Lafarge	11
19	JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone 2012 ·Blood ·Anna L. Godfrey, Edwin Chen, Francesca Pagano, Christina A. Ortmann, Yvonne Silber, Beatríz Bellosillo, Paola Guglielmelli, Claire Harrison, John T. Reilly, Frank Stegelmann, Fontanet Bijou, Éric Lippert, Mary Frances McMullin, Jean‐Michel Boiron, Konstanze Döhner, Alessandro M. Vannucchi, Carlos Besses, Peter J. Campbell, Anthony R. Green	68
20	Thrombopoietin to replace megakaryocyte‐derived growth factor: impact on stem and progenitor cells during ex vivo expansion of CD34+ cells mobilized in peripheral blood 2010 ·Transfusion ·Pascale Duchez, J. Chevaleyre, Marija Vlaski‐Lafarge, Bernard Dazey, Fontanet Bijou, Xavier Lafarge, Nöel Milpied, Jean‐Michel Boiron, Zoran Ivanović	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact